AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
46.68
+0.47 (1.02%)
At close: Jan 21, 2026, 4:00 PM EST
46.68
0.00 (0.00%)
After-hours: Jan 21, 2026, 4:11 PM EST
AnaptysBio Revenue
AnaptysBio had revenue of $76.32M in the quarter ending September 30, 2025, with 154.26% growth. This brings the company's revenue in the last twelve months to $169.47M, up 196.42% year-over-year. In the year 2024, AnaptysBio had annual revenue of $91.28M with 432.03% growth.
Revenue (ttm)
$169.47M
Revenue Growth
+196.42%
P/S Ratio
8.02
Revenue / Employee
$1,246,081
Employees
136
Market Cap
1.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | 5.00M | -5.00M | -50.00% |
| Dec 31, 2017 | 10.00M | -6.68M | -40.06% |
| Dec 31, 2016 | 16.68M | -887.00K | -5.05% |
| Dec 31, 2015 | 17.57M | 1.73M | 10.94% |
| Dec 31, 2014 | 15.84M | 10.36M | 188.86% |
| Dec 31, 2013 | 5.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.06B |
| Xeris Biopharma Holdings | 266.14M |
| Day One Biopharmaceuticals | 133.67M |
| Immatics | 99.45M |
| EyePoint | 42.34M |
| AbCellera Biologics | 35.33M |
| Capricor Therapeutics | 11.13M |
| Relay Therapeutics | 8.36M |
ANAB News
- 7 days ago - AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - Reuters
- 13 days ago - Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary - GlobeNewsWire
- 15 days ago - Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 2 months ago - Anaptys Announces Participation in December Investor Conferences - GlobeNewsWire
- 2 months ago - AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
- 2 months ago - GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga